Press release
Atopic Dermatitis Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Pfizer, AOBiome, Allakos, Eli Lilly, Arcutis, Alphyn, Argenx, Qurient, Merck, GI Innovation, AnaptysBio
"Atopic Dermatitis Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Atopic Dermatitis Therapeutics Market.
The report provides a detailed description of the Atopic Dermatitis drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Atopic Dermatitis Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Atopic Dermatitis Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Atopic Dermatitis therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Dermatitis treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Atopic Dermatitis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Atopic Dermatitis treatment market.
Learn More about the Clinical and Commercial Development Activities in the Atopic Dermatitis Therapeutics Domain @
https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Atopic Dermatitis Therapeutics Analysis
There is currently no specific test for Atopic Dermatitis, and no single symptom or feature can be used to identify the disease. Each patient has a unique combination of symptoms and rash appearance. Diagnosis of Atopic Dermatitis is based on the history and physical examination of the patient. In uncertain cases, a skin biopsy may be taken for a histopathological diagnosis of dermatitis.
Currently, there is no cure for Atopic Dermatitis; however, it can be effectively managed with current treatment options. The pattern of the disease and its severity determine the kind of treatment the patient ought to receive. Treatment options include topical treatments like emollients, topical corticosteroids (TCS), antibiotics, topical calcineurin inhibitors (TCIs), and systemic treatments such as immunosuppressant, corticosteroids, and phototherapy. Drugs such as Eucrisa (Crisaborole), Dupixent (Dupilumab), and others are approved for Atopic Dermatitis.
There are approximately 100+ pharma and biotech companies actively engaged in developing therapies for Atopic Dermatitis. Notably, Dermavant Sciences is among the leading companies with Atopic Dermatitis drug candidates in the most advanced stage of development-Phase III clinical trials.
Atopic Dermatitis Companies in the Therapeutics Market Include:
Some of the key companies in the Atopic Dermatitis Market include Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd., GI Innovation, AnaptysBio, MC2 Therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and many others.
Emerging and Marketed Atopic Dermatitis Therapies Covered in the Report Include:
• Tapinarof: Dermavant Sciences
• Etrasimod: Pfizer
• B244: AOBiome
• Lirentelimab: Allakos Inc.
• QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
• Nemolizumab: Galderma
• Rinvoq: Abbvie
• Bermekimab : Janssen Pharmaceutical
• Etrasimod: Arena Pharmaceuticals
• Abrocitinib: Pfizer
• Lebrikizumab: Eli Lily
• FB825: Oneness Biotech
And Many Others
Get an in-depth Assessment of the Emerging Therapies and Atopic Dermatitis Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Atopic Dermatitis Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates
Route of Administration
Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Molecule Type
Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Request for Sample PDF to Understand More About the Atopic Dermatitis Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Atopic Dermatitis Current Treatment Patterns
4. Atopic Dermatitis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Atopic Dermatitis Late-Stage Products (Phase-III)
7. Atopic Dermatitis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Atopic Dermatitis Discontinued Products
13. Atopic Dermatitis Product Profiles
14. Atopic Dermatitis Companies
15. Atopic Dermatitis Drugs
16. Dormant and Discontinued Products
17. Atopic Dermatitis Unmet Needs
18. Atopic Dermatitis Future Perspectives
19. Atopic Dermatitis Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Atopic Dermatitis Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Pfizer, AOBiome, Allakos, Eli Lilly, Arcutis, Alphyn, Argenx, Qurient, Merck, GI Innovation, AnaptysBio here
News-ID: 3353494 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Atopic
Atopic Dermatitis Market Trends That Will Shape the Next Decade: Insights from P …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
How Large Will the Atopic Dermatitis Market Size By 2025?
The market size for atopic dermatitis has seen significant expansion in the past few years. This expansion is anticipated to continue, with the market size increasing from $8.61 billion in 2024 to $9.96 billion in 2025, exhibiting a compound annual growth rate (CAGR) of…
Atopic Dermatitis Pipeline Outlook Report 2024
DelveInsight's, "Atopic Dermatitis Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including Atopic Dermatitis clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Atopic Dermatitis Pipeline…
Advanced Therapy Revolutionizes Atopic Dermatitis Market Prospects
The atopic dermatitis market size is expected to be valued at USD 15.42 Billion in 2024 and reach USD 30.5 Billion by 2029, growing at a CAGR of 14.5 % from 2024 to 2029.
Atopic dermatitis, known as eczema, is a prevalent skin condition marked by red, inflamed, and itchy skin. It is a chronic condition commonly seen in children but can also impact adults. Atopic dermatitis is thought to result…
Atopic Dermatitis - Drug Pipeline Landscape, 2023
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may crak and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness. Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger…
Atopic Dermatitis - Drug Pipeline Landscape, 2022
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may cr*ck and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness.
Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger an…
Atopic Dermatitis (Atopic Eczema) Treatment Market Business Growth And Industry …
Precision Business Insights published a research report on “Atopic Dermatitis (Atopic Eczema) Treatment Market by Drug type (Corticosteroids, Calcineurin Inhibitors, Immunosuppressants, Phosphodiesterase type 4 (PDE-4) Inhibitors, Antibiotics, Antihistamines, Emollients), Route of administration (Oral, Topical, Parenteral), Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography - Global/Region/Country Forecast to 2027”.
In people who suffer from atopic dermatitis, allergies play a big influence. When the patient is exposed to…
